



Coronary vasospasm induced by aminophylline after negative dipyridamole stress echocardiography: a case report

Lauro Cortigiani^{1*} , Davide Donelli² , Francesco Bovenzi¹

¹Division of Cardiology, San Luca Hospital, 55100 Lucca, Italy

²Cardiology Department, Parma University Hospital, 43126 Parma, Italy

***Correspondence:** Lauro Cortigiani, Division of Cardiology, San Luca Hospital, 55100 Lucca, Italy. lacortig@tin.it

Academic Editor: Dimitrios Tousoulis, Athens University Medical School, Greece

Received: May 17, 2025 **Accepted:** July 4, 2025 **Published:** July 13, 2025

Cite this article: Cortigiani L, Donelli D, Bovenzi F. Coronary vasospasm induced by aminophylline after negative dipyridamole stress echocardiography: a case report. *Explor Cardiol.* 2025;3:101263. <https://doi.org/10.37349/ec.2025.101263>

Abstract

We report the case of a 58-year-old patient with chronic ischemic syndrome who underwent dipyridamole stress echocardiography for the evaluation of chest pain. The stress test was negative with normal coronary flow velocity reserve, preserved chronotropic competence, and no inducible wall motion abnormalities. However, upon administration of aminophylline at the end of the test, the patient developed acute chest pain, ST-segment elevation, and severe apical wall motion abnormalities. These findings resolved with intravenous nitrates. Subsequent coronary angiography revealed a significant vasospastic stenosis in the left anterior descending artery superimposed on a mild organic stenosis of around 50% after intracoronary nitrates. The coronary stenosis was successfully treated with a drug-eluting stent. This case highlights the potential for vasospastic angina to be unmasked following vasodilator reversal, even after a negative stress echocardiography.

Keywords

Aminophylline, coronary vasospasm, stress echocardiography, vasospastic angina, case report

Introduction


Vasospastic angina (VSA), characterized by transient coronary artery spasm leading to myocardial ischemia, is a known but often underrecognized cause of chest pain, particularly when angiographically significant stenosis is absent or minimal [1]. Dipyridamole stress echocardiography is a commonly used non-invasive test to assess myocardial ischemia. Typically, a negative test suggests low likelihood of flow-limiting coronary disease. However, rare paradoxical responses, particularly after the administration of aminophylline, have been reported to provoke coronary spasm and reveal underlying VSA [2–5]. This case demonstrates the rare occurrence of coronary vasospasm triggered by aminophylline after a negative dipyridamole stress echocardiography. It adds to the literature by highlighting a paradoxical response during vasodilator reversal.



Case report

A 58-year-old female with a history of typical chest pain at rest that had been onset for approximately 4 weeks and whose attacks had become increasingly frequent (2–3 per day) was referred for dipyridamole stress echocardiography. Risk factors included hypertension and smoking.

Baseline echocardiography showed preserved left ventricular ejection fraction and no regional wall motion abnormalities. Stress was performed with the recommended methodology and standards [6]. During dipyridamole infusion, coronary flow velocity reserve (CFVR) in the mid-distal left anterior descending (LAD) coronary artery was within normal limits (> 2.0) (Figure 1), chronotropic reserve was preserved, defined as stress heart rate/rest heart rate > 1.22 , and no inducible ischemia or wall motion abnormalities were observed. The test was considered negative for ischemia.



$$\text{CFVR} = \frac{72}{28} = 2.57$$

Figure 1. CFVR in LAD. Normal increase of diastolic coronary flow velocity (CFVR = 2.57) from rest (left) to peak stress (right). CFVR: coronary flow velocity reserve; LAD: left anterior descending

To reverse the vasodilatory effects of dipyridamole, aminophylline was administered. Immediately following its infusion, the patient experienced:

- Acute substernal chest pain;
- ST-segment elevation on electrocardiogram (ECG) (antero-apical and lateral leads) (Figure 2);
- Development of apical regional wall motion abnormality on echocardiography (Figure 3).

Prompt administration of intravenous nitrates led to rapid resolution of symptoms, normalization of ECG changes, and recovery of apical wall motion.

The patient underwent urgent coronary angiography, which revealed a spontaneous focal, tight vasospastic stenosis in the mid-LAD segment (Figure 4) which was partially relieved by intracoronary nitrates, confirming the diagnosis of VSA. After nitrates an organic stenosis of around 50% was observed and treated with a drug-eluting stent (DES) to prevent recurrent spasm and ensure vessel patency.

The patient reported feeling well after the procedure and did not experience further symptoms. Figure 5 summarizes the timeline of the events.

Discussion

This case illustrates a rare but clinically significant phenomenon: the unmasking of VSA following aminophylline administration at the end of a dipyridamole stress test. While dipyridamole typically induces




Figure 2. ST-segment elevation in anterolateral leads after aminophylline and chest pain. The 12-lead ECG was not technically satisfactory since the patient was immediately rushed to the catheterization laboratory. ECG: electrocardiogram




Figure 3. End-systolic frames from apical 5-chamber view showing a small left ventricle with normal regional wall motion at peak stress (left panel) and severe cavity dilation with apical akinesia after aminophylline (right panel)

coronary vasodilation via adenosine-mediated pathways, its reversal with aminophylline—an adenosine receptor antagonist—may paradoxically lead to coronary vasoconstriction in susceptible individuals [7].

The development of symptoms and ischemic ECG changes in this context, despite a negative stress test, suggests that the patient's symptoms were due to dynamic coronary spasm rather than fixed atherosclerotic obstruction. This supports the concept that normal CFVR and wall motion during pharmacologic stress testing do not exclude coronary vasomotor disorders.

Coronary vasospasm has been reported in association with various pharmacologic provocations, and in some cases, the administration of aminophylline or even the withdrawal of vasodilators can induce spasm. By blocking vasodilatory A2A receptors in coronary vessels, aminophylline removes adenosine's vasodilatory effect, potentially resulting in unopposed vasoconstriction, especially in vessels with impaired endothelial function or spasm-prone segments. Aminophylline is a methylxanthine (like caffeine and theophylline). It also increases catecholamine release (e.g., norepinephrine) by antagonizing presynaptic adenosine A1 receptors. This sympathetic activation can result in vasoconstriction through alpha-1

LAD at rest



LAD during spasm



Figure 4. Coronary angiographic findings. Coronary vasospasm of proximal LAD resolved after intracoronary administration of nitrates, showing a residual mild 50% stenosis. LAD: left anterior descending




Figure 5. Timeline of events. CFVR: coronary flow velocity reserve; ECG: electrocardiogram

receptor activation by norepinephrine, but this is an indirect effect, not due to aminophylline acting on alpha-1 receptors itself [8]. Management typically includes calcium channel blockers and nitrates [9], and the decision to stent the underlying organic coronary lesion can be associated with recurrence of symptoms due to persisting vasospasm not treated by stenting [10].

In this case, the decision to stent the culprit segment was driven by the severity of the stenosis and the clinical presentation, as symptoms in these patients were refractory to medical therapy and persisted despite intensive treatment. As reported in the literature, stenting mild-to-moderate coronary stenoses can be safe and effective in selected patients [11]. However, we recommend that the decision be individualized, taking into account the clinical presentation, response to medical therapy, and anatomical accessibility of the coronary stenosis.

In conclusion, clinicians should be aware of the potential for coronary vasospasm, particularly after pharmacologic stress testing. A negative dipyridamole test does not exclude VSA, and aminophylline can, in rare cases, precipitate coronary spasm.

Abbreviations

CFVR: coronary flow velocity reserve

DES: drug-eluting stent

ECG: electrocardiogram

LAD: left anterior descending

VSA: vasospastic angina

Declarations

Author contributions

LC: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. DD: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. FB: Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The Declaration of Helsinki (2024 version) was adequately addressed, and the study was approved by the institutional ethics committees in its latest versions as part of the more comprehensive Stress Echo 2030 study 291/294/295 Comitato Etico Lazio-1, March 8, 2021; Clinical trials (<https://clinicaltrials.gov/>). Gov Identifier NCT05081115.

Consent to participate

Informed consent to participate in the study was obtained from the participant.

Consent to publication

Informed consent to publication was obtained from relevant participant.

Availability of data and materials

Data will not be shared as it involves patients' privacy, but may be available from the corresponding author upon reasonable request.

Funding

Not applicable.

Copyright

© The Author(s) 2025.

Publisher's note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

1. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. *Circulation*. 2011;124:1774–82. [DOI] [PubMed]
2. Picano E, Lattanzi F, Masini M, Distante A, L'Abbate A. Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina. *Am J Cardiol*. 1988;62:694–7. [DOI] [PubMed]
3. Weinmann P, Le Guludec D, Moretti JL. Coronary spasm induced by dipyridamole during a myocardial scintigraphy. *Int J Cardiol*. 1994;43:75–8. [DOI]
4. Baldini U, Dini FL, Marchetti M, Micheli G, Magini G. Dipyridamole-echocardiography test in the diagnosis of vasomotor angina. *G Ital Cardiol*. 1997;27:1169–73. Italian. [PubMed]
5. Li KFC, Ho HH, Yew MS. A case report of dipyridamole stress-induced ST depression progressing to ST-elevation myocardial infarction despite intravenous aminophylline: steal, spasm, or something else? *Eur Heart J Case Rep*. 2019;3:ytz054. [DOI] [PubMed] [PMC]
6. Picano E, Pierard L, Peteiro J, Djordjevic-Dikic A, Sade LE, Cortigiani L, et al. The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC. *Eur Heart J Cardiovasc Imaging*. 2024;25:e65–90. [DOI] [PubMed]
7. Djordjevic Dikic A, Dedic S, Boskovic N, Giga V. Coronary vasospasm testing: escape from the cath lab! *Explor Cardiol*. 2024;2:1–8. [DOI]
8. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: from research into clinical practice. *Circulation*. 2012;126:753–67. [DOI] [PubMed] [PMC]
9. Om SY, Yoo SY, Cho GY, Kim M, Woo Y, Lee S, et al. Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm. *JACC Cardiovasc Imaging*. 2020;13:1875–87. [DOI] [PubMed]
10. Kim JH, Park J, Yang Y, Lee S, Kim DH, Song JM, et al. Percutaneous coronary intervention in patients with documented coronary vasospasm during long-term follow-up. *Heart*. 2022;108:1303–9. [DOI] [PubMed]
11. Chu G, Zhang G, Zhang Z, Liu S, Wen Q, Sun B. Clinical outcome of coronary stenting in patients with variant angina refractory to medical treatment: a consecutive single-center analysis. *Med Princ Pract*. 2013;22:583–7. [DOI] [PubMed] [PMC]